A blinded, dose-escalating phase IIa study of the fVII/tissue factor inhibitor rNAPc2 in patients undergoing elective percutaneous coronary angioplasty - Moons, A; Bijsterveld, N; Büller, H; Prins, M; Rote, WE; Vlasuk, GP; Peters, RJ (Blood, 2001)
(abstract).